Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Champions Oncology, Inc is a biotechnology business based in the US. Champions Oncology shares (CSBR) are listed on the NASDAQ and all prices are listed in US Dollars. Champions Oncology employs 143 staff and has a trailing 12-month revenue of around USD$34.9 million.
|Latest market close||USD$10.67|
|52-week range||USD$4.02 - USD$10.28|
|50-day moving average||USD$8.6811|
|200-day moving average||USD$8.7862|
|Wall St. target price||USD$11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.092|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-6.49%|
|1 month (2020-11-05)||14.98%|
|3 months (2020-09-04)||33.04%|
|6 months (2020-06-05)||18.29%|
|1 year (2019-12-05)||45.96%|
|2 years (2018-12-04)||-4.90%|
|3 years (2017-12-05)||189.95%|
|5 years (2015-12-02)||151.41%|
Valuing Champions Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Champions Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Champions Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$90,000.
The EBITDA is a measure of a Champions Oncology's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$34.9 million|
|Gross profit TTM||USD$15.2 million|
|Return on assets TTM||-2.87%|
|Return on equity TTM||-34.77%|
|Market capitalisation||USD$119.7 million|
TTM: trailing 12 months
There are currently 140,242 Champions Oncology shares held short by investors – that's known as Champions Oncology's "short interest". This figure is 1.4% up from 138,364 last month.
There are a few different ways that this level of interest in shorting Champions Oncology shares can be evaluated.
Champions Oncology's "short interest ratio" (SIR) is the quantity of Champions Oncology shares currently shorted divided by the average quantity of Champions Oncology shares traded daily (recently around 28856.378600823). Champions Oncology's SIR currently stands at 4.86. In other words for every 100,000 Champions Oncology shares traded daily on the market, roughly 4860 shares are currently held short.
However Champions Oncology's short interest can also be evaluated against the total number of Champions Oncology shares, or, against the total number of tradable Champions Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Champions Oncology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Champions Oncology shares in existence, roughly 10 shares are currently held short) or 0.0283% of the tradable shares (for every 100,000 tradable Champions Oncology shares, roughly 28 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Champions Oncology.
Find out more about how you can short Champions Oncology stock.
We're not expecting Champions Oncology to pay a dividend over the next 12 months.
Champions Oncology's shares were split on a 1:12 basis on 12 August 2015. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Champions Oncology shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Champions Oncology shares which in turn could have impacted Champions Oncology's share price.
Over the last 12 months, Champions Oncology's shares have ranged in value from as little as $4.02 up to $10.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Champions Oncology's is 1.1059. This would suggest that Champions Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.